FDA Panel Votes Against Drugs Said to Prevent Prostate
Cancer
(HealthDay): "HealthDay - WEDNESDAY, Dec. 1 (HealthDay News) -- A U.S. Food and Drug
Administration advisory committee on Wednesday voted against approving
two drugs for the prevention of prostate cancer, the third-highest cancer
killer of men."
The panel voted 17-0, with one abstention, that the risks of Merck's Proscar outweighed its benefits, according to the Associated Press. And in a similar vote, the panel voted 14-2, with two abstentions, against GlaxoSmithKline's Avodart. Both drugs are already approved to treat enlarged prostates.
